| Literature DB >> 26011159 |
Amy E Armstrong1, Debra E Weese-Mayer2, Amir Mian3, John M Maris4, Vandana Batra4, Yasmin Gosiengfiao5, Jennifer Reichek5, Mary Beth Madonna6, Jonathan W Bush7, Richard M Shore8, David O Walterhouse5.
Abstract
Neuroblastoma in patients with congenital central hypoventilation syndrome (CCHS) as part of a neurocristopathy syndrome is a rare finding and has only been associated with paired-like homeobox 2b (PHOX2B) non-polyalanine-repeat-expansion mutations. To the best of our knowledge, we report the first case of a child with CCHS and Hirschsprung disease who had a PHOX2B polyalanine-repeat-expansion mutation (PARM) (genotype 20/33) and developed high-risk neuroblastoma. We further describe his treatment including chemotherapy and therapeutic I(131) -metaiodobenzylguanidine. This case highlights the need to consider neuroblastoma in patients with CCHS and the longest PHOX2B PARMs and to individualize treatment based on co-morbidities.Entities:
Keywords: MIBG; PHOX2B; chemotherapy; congenital central hypoventilation syndrome; neuroblastoma; neurocristopathy
Mesh:
Substances:
Year: 2015 PMID: 26011159 DOI: 10.1002/pbc.25572
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167